To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Provider Data DescriptionPrimary (control portion of the study): Assess the safety and tolerability of G1T28 administered with E/P therapy
Secondary (control portion of the study): Assess the hematologic profile (kinetics and incidence/duration/frequency of toxicities) of G1T28 administered with E/P therapy; Assess the incidence of febrile neutropenia; Assess the incidence of infections; Assess the utilization of RBC and platelet transfusions; Assess the utilization of hematopoietic growth factors ; Assess the utilization of systemic antibiotics; Assess the incidence of chemotherapy dose reductions and dose interruptions overall; Assess the incidence of Grade 2 or greater nephrotoxicity ; Assess tumor response based on RECIST, Version 1.1; Assess PFS and overall survival
***Complete list can be found in the NCT listing.
SponsorG1 Therapeutics, Inc.
Data ProviderG1 Therapeutics, Inc.
Partial set or SubsetOriginal Data
Patients in dataset77
# of Patients Control38
# of Patients ExperimentalN/A
Study ArmsComparator arm data only
Clinical Trials.gov Information
Brief SummaryThis is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC.
The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.